ArticleMolecular neurobiology2026
Up-regulated miR-4443 Holds Diagnostic Significance for Parkinson's Disease and may be Involved in Neuroinflammation.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a widespread neurodegenerative disorder. MicroRNAs (miRNAs) have emerged as crucial regulatory molecules in the context of PD. Exploring the diagnostic significance of miR-4443 in PD and its impacts on microglial inflammatory responses. The present study enrolled 95 PD patients and 90 healthy controls. The expression levels of miR-4443 and EBF3 and their diagnostic potential for PD were analyzed using RT-qPCR and a ROC curve. LPS-treated BV2 microglial cells were utilized to simulate the neuroinflammatory process in PD pathogenesis. Cell proliferation activity was assessed using the CCK-8 assay. ELISA was employed to measure cellular pro-inflammatory cytokine levels. To confirm the putative binding between miR-4443 and EBF3, a dual-luciferase reporter assay was conducted. The expression level of miR-4443 was significantly up-regulated in the serum of PD patients, and it exhibited diagnostic potential for PD. Following LPS induction in BV2 microglial cells, miR-4443 expression was up-regulated. Overexpression of this miRNA suppressed proliferation and enhanced pro-inflammatory cytokine release. Conversely, miR-4443 knockdown reversed the resultant phenotypic changes. EBF3 was verified to have a binding relationship with miR-4443. Functional experiments indicated that miR-4443 might participate in the neuroinflammatory process of PD pathogenesis by targeting EBF3. Up-regulated miR-4443 has diagnostic significance for PD and may participate in neuroinflammation through regulating EBF3.
Indexed as
Identifiers
41606222What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.